Acrylamide-induced molecular mutation spectra at HPRT locus in human promyelocytic leukaemia HL-60 and NB4 cell lines.

Mutagenesis

Department of Hygienic Toxicology, Preventive Medical College, Third Military Medical University, Chongqing 400038, People's Republic of China.

Published: July 2008

Acrylamide (AA) is a compound widely used in many industries around the world. The recent finding that it is formed naturally in foods by heating raises human health concerns. AA is a proven carcinogen in animals and a probable carcinogen in humans, while its mutagenicity detected using in vitro mammalian gene mutation assays is still inconsistent in different cell systems. In the present study, we investigated the mutagenicity of AA in human promyelocytic leukaemia cells, HL-60 and NB4 cells, by examining the mutations at the hypoxanthine-guanine phosphoribosyltransferase (HPRT) gene locus. In a 6-h treatment without the exogenous activation, AA exerted a weak mutagenic effect at the highest concentration used in the study (700 mg/l) in HL-60 cells (P < 0.01) as well as in NB4 cells (P < 0.05). Molecular analysis of AA-induced mutants revealed a different mutation spectrum, when compared to that of spontaneous mutants. The most frequent spontaneous mutations were point mutations, whereas AA-induced mutations were mainly single exon deletions besides point mutations, and an increase in the proportion of partial deletion was associated with the increase of AA treatment. There was no obvious difference in the mutation spectra observed between the HL-60 and NB4 cell lines. These results showed that AA has a weak mutagenic effect at HPRT gene locus in human promyelocytic leukaemia HL-60 and NB4 cell lines and those molecular mutation spectra (single exon deletions and point mutations) may be related to some specific and precise mechanism.

Download full-text PDF

Source
http://dx.doi.org/10.1093/mutage/gen016DOI Listing

Publication Analysis

Top Keywords

hl-60 nb4
16
mutation spectra
12
human promyelocytic
12
promyelocytic leukaemia
12
nb4 cell
12
cell lines
12
point mutations
12
molecular mutation
8
locus human
8
leukaemia hl-60
8

Similar Publications

A novel therapeutic strategy for leukopenia: Miltefosine activates the Ras/MEK/ERK pathway to promote neutrophil differentiation.

Biochem Biophys Res Commun

February 2025

Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, China. Electronic address:

Leukopenia, marked by diminished white blood cell (WBC) counts, presents significant challenges in the management of hematological malignancies and immunocompromised patients. This study evaluated the therapeutic potential of miltefosine (MFS), a phospholipid analogue, for treating leukopenia. In vitro studies using HL60 and NB4 cells revealed that MFS effectively promoted neutrophil differentiation and function, evidenced by the upregulation of surface markers CD11b, CD11c, CD14, and CD15, as well as enhanced bactericidal activity assessed through the NBT reduction assay.

View Article and Find Full Text PDF

Differentiation therapy with all-trans retinoic acid (ATRA) is well established for acute promyelocytic leukemia (APL). However, the narrow application and tolerance development of ATRA remain to be improved. A number of kinase inhibitors have been reported to induce cell differentiation.

View Article and Find Full Text PDF

MEF2A is a transcription factor for circPVT1 and contributes to the malignancy of acute myeloid leukemia.

Int J Oncol

November 2024

Department of Hematology, Hematology Research Center of Yunnan Province, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China.

Article Synopsis
  • Acute myeloid leukemia (AML) has a high risk of relapse and poor survival, with key roles played by circPVT1 and MEF2A in cancer progression that are still being investigated.
  • Research showed that circPVT1 is overexpressed in AML and is regulated by MEF2A, which enhances cell survival and promotes processes linked to cancer spread called epithelial-mesenchymal transition (EMT).
  • CircPVT1 targets microRNA (miR)-455-3p, influencing the regulation of the MCL1 protein to facilitate cancer cell viability and EMT, suggesting that interrupting this pathway could be a potential therapeutic approach for AML.
View Article and Find Full Text PDF
Article Synopsis
  • Differentiation therapy with all-trans retinoic acid (ATRA) is effective for acute promyelocytic leukemia (APL), but there are limitations in its tolerance and application that prompted researchers to seek new inducers of myeloid differentiation.
  • The study identified the kinase inhibitors PD169316, SB203580, SB202190, and triciribine (TCN) as potent enhancers of CD11b expression in APL cells, with a focus on TCN due to its good tolerance in patients.
  • TCN promotes the differentiation of APL and acute myeloid leukemia (AML) cells by activating the ERK pathway and enhancing pathways associated with hematopoietic lineage and cytokine interactions, revealing
View Article and Find Full Text PDF

Combining new therapeutics with all--retinoic acid (ATRA) could improve the efficiency of acute myeloid leukemia (AML) treatment. Modeling the process of ATRA-induced differentiation based on the transcriptomic profile of leukemic cells resulted in the identification of key targets that can be used to increase the therapeutic effect of ATRA. The genome-scale transcriptome analysis revealed the early molecular response to the ATRA treatment of HL-60 cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!